Key Points
- CEO Mahesh Patel bought 25,000 shares at an average price of $2.02 on April 2, spending $50,500 and increasing his holdings to 135,679 shares (a 22.59% rise), according to an SEC filing.
- Lipocine shares trade near $2 and are down about 77.8% with a market cap of roughly $15M; the company recently beat quarterly EPS and revenue estimates (EPS -$0.34 vs. -$0.60; revenue $1.15M) but remains loss-making and carries mixed analyst ratings with an average target of $15.
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of the company's stock in a transaction on Thursday, April 2nd. The stock was bought at an average cost of $2.02 per share, for a total transaction of $50,500.00. Following the acquisition, the chief executive officer directly owned 135,679 shares of the company's stock, valued at $274,071.58. This represents a 22.59% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Lipocine Stock Down 77.8%
LPCN opened at $2.05 on Friday. The firm has a market cap of $14.97 million, a PE ratio of -1.22 and a beta of 1.09. The business has a fifty day simple moving average of $8.45 and a 200-day simple moving average of $5.75. Lipocine Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $12.37.
Lipocine (NASDAQ:LPCN - Get Free Report) last announced its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million.
Analysts Set New Price Targets
Several research firms have issued reports on LPCN. Weiss Ratings restated a "sell (d-)" rating on shares of Lipocine in a report on Friday, March 27th. Wall Street Zen raised shares of Lipocine from a "sell" rating to a "hold" rating in a research report on Sunday, March 22nd. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price target (up from $7.00) on shares of Lipocine in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Lipocine presently has an average rating of "Moderate Buy" and an average target price of $15.00.
Get Our Latest Report on LPCN
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC acquired a new stake in shares of Lipocine in the 3rd quarter valued at $41,000. Jane Street Group LLC bought a new position in Lipocine during the fourth quarter valued at about $85,000. Squadron Capital Management LLC bought a new stake in shares of Lipocine in the 4th quarter worth about $4,256,000. Diadema Partners LP acquired a new stake in Lipocine in the 4th quarter valued at about $2,095,000. Finally, Ikarian Capital LLC bought a new position in shares of Lipocine in the 4th quarter valued at about $1,602,000. Hedge funds and other institutional investors own 9.11% of the company's stock.
Lipocine Company Profile
(
Get Free Report)
Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company's core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.
The company's lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
